Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Team Novo Nordisk

- PMLiVE

Inizio announced as headline sponsor for 2026 Communiqué Awards

The PMGroup Awards celebrate excellence in health communications

- PMLiVE

Communiqué 2025: celebrating excellence in healthcare communications

This year’s Awards, held at the Grosvenor House Hotel in London on 3 July, included 30 categories

people hold signs with speech bubbles

The importance of appropriate language when raising awareness of a disease

Using the right language in disease awareness campaigns can help help save lives. Here we share top tips on how to use language that is accessible, inclusive and engaging.

Say Communications

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

regeneron headquarters

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

- PMLiVE

Examining the health of the pharma: patient group relationship

Explore the positive aspects and areas for improvement in the relationship between patient advocacy groups and pharma companies when participating in research, educational initiatives and awareness campaigns.

Say Communications

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

Putting EU Lab Day on the Map

EU Lab Day 2024 made an impact - reaching over 1.7million people through media and social.

EatMoreFruit

- PMLiVE

Sanofi unveils plans to build €1bn insulin production base in China

The site will focus on serving the insulin medication needs of local diabetic patients

- PMLiVE

Common antidiabetic drug metformin found to slow growth of precancerous cells

The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

- PMLiVE

Communiqué Awards

Announcement about the results of the Media Relations category

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links